Reaction
Biopsy Bone Marrow reporting signals
As of the last recalculation, Biopsy Bone Marrow appears in 461 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 143.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 126 | 143.7 | 144.0 |
| Avapritinib | 14 | 53.8 | 53.9 |
| Epoprostenol | 13 | 46.1 | 46.2 |
| Deferasirox | 15 | 26.4 | 26.4 |
| Venetoclax | 26 | 20.1 | 20.2 |
| Azacitidine | 12 | 18.7 | 18.7 |
| Eltrombopag Olamine | 9 | 18.0 | 18.0 |
| Azacitidine For | 7 | 17.6 | 17.6 |
| Ravulizumab | 5 | 16.9 | 16.9 |
| Relugolix | 4 | 7.7 | 7.7 |